AIHTA - Publications - Search - Tislelizumab (Tevimbra®) in combination with gemcitabine and cisplatin for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma

Rothschedl, E. and Wolf, S. (2025): Tislelizumab (Tevimbra®) in combination with gemcitabine and cisplatin for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma. Fact Sheet Nr. 233.

[thumbnail of Fact Sheet Nr.233.pdf]
Preview
 PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
575kB

Item Type:Horizon Scanning of Medicines
Subjects:QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
QZ Pathology > QZ 200-380 Neoplasms.Cysts
WB Practice of medicine > WB 300-962 Therapeutics
WV Otolaryngology > WV 300-358 Nose and paranasal sinuses
WV Otolaryngology > WV 400-440 Pharyngeal region
Language:English
Series Name:Fact Sheet Nr. 233
Deposited on:13 Nov 2025 18:05
Last Modified:13 Nov 2025 18:05

Repository Staff Only: item control page